We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Point taken but it's not difficult to be despondent with GSK. Minus 3% tomorrow would not surprise me..........
So you stick with a share for years then just as it gets any momentum you sell? IMO madness. Thereās been nothing but good news for a while, that will take time to feed in to the results. If they can get past the litigation, I canāt see much holding gsk back from at least getting to parity with its peers.
52 week high Ā£16.70. Looking at my shares after the HLN split with dividends it's finally looking a bit more promising. Get to even and run away.....
Just in case you missed it :_
Deutsche Bank raises GSK price target to 1,950 (1,850) pence - 'buy'
....this will be new floor!
NervousNelly, we are grateful that you read your tea leaves this morning, though it is a pity, those same tea leaves, failed to advise you that you would go in the GSK, site instead of your normal LGEN, site. Unfortunately, you failed to provide, any words of wisdom on the GSK, equity, which is just as well because LGEN, fundamentals, would not be relevant.
No matter what the word is on people who go by charts etc. With GSK settling the Zantac claim out of court with no claim of liability this has got to be good news for us long termers. I've already put my money where my mouth is this morning and added to my holding. GLA
As expected the sp, retraced with profit taking at 1600 level, which is where the long term upward sloping resistance line is situated . The recent Bollinger band high of 1631, was not breached, and the equity is falling back to the region of yesterday's Bollinger band high. Long term support for GSK, is situated at the up sloping trend line at 1500. DYOR.
Looks like others on the zoom were impressed. Iām very happy with my top up this morning. The fall was unwarranted, surprised that it changed round intraday but it doesnāt really matter as these are a long term hold. The market should start to appreciate gsk at some point and I will be here when it does.
[GSK] I joined the Zoom call at 11.00 to see if I could detect anything in the fundamentals that would justify the initial fall in share price. I couldn't. The full year figures were good but were expected to be; what was new was the rise in the sales, profit and eps growth in the period 2026 - 31. They expect 12 new product launches in this period and that margins will remain "stable" despite loss of patent protection on some drugs. What came out was that these are "risk adjusted" (kept modest) projections. They did show a non risk adjusted growth projection which phenomenal. With debt coming down, growth going up and margins not deteriorating I broke my usual rules and increased my holding at 1534p during the meeting. This stock is cheap relative to other pharmaceutical companies and doing well in a couple of well defined niches, yes, I know Zantac overshadows the company but with free cash flow of over Ā£3.4b per year would they not survive if the drug was proved to have a very low rate of carcinogenesis? I see the stock is going up post the meeting so Romeike you may yet see your Ā£18 - 20 level.
Because there was a run up ahead of results in anticipation they would be good. Some of those are now profit taking on their call and closing long contracts. I'm expecting a move back up towards 18-20 level once the news from Delaware is out.
Iām going to keep buying. In comparison to its peers gsk is undervalued. Nothing to warrant a drop today.
So unloved, donāt understand.
Can't believe we're down after that update. Same reaction as the last good update!
ZANTAC , Liability???
What didnāt market like?
July 12th this year!
Woha ...what is all this share enthusiasm?
Older Whatās the date?
This stick is frustrating, but it hasnāt broken my faith yet. Iām still buying. If we donāt get a boost from the end of the litigation Iāll reassess then.
....and still our SP falls!
I am going to mark a date in my diary and if this is not then subject to a bid or at least Ā£17.50, I shall reluctantly say goodbye.
Citi raised its target price on GSK from 1535p to 1700p. The bank has now increased its core earnings per share estimates for 2030 to 2035 by between 19% and 43%. They particularly like the recent Bellus and Aiolos respiratory deals addressing de-risked targets in a core therapeutic area of competence for GSK. Citi has also raised its forecasts for ViiV - āassuming the next generation therapies with larger dosing windows translate into higher adoption ratesā.
...shows Citi giving us the thumbs up after many years. Let's hope a few more big institutions come out in support and this SP finally firms up.
Some of the most robust evidence (suggesting no evidence of a link between ranitidine with cancer) was published in Sept 2023 in the The Journal of the American Medical Association (JAMA). Link below -
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10509724/
I have no idea how the ambulance chasers are going to dismiss this large multinational credible study, especially as its validity is supported by the publication in a leading peer reviewed American journal.
Another unjustified drop in SP yesterday, for a hearing in Delaware weāve known about for some time? GSKs defence seems pretty strong.. Yes, there is a theoretical risk that NDMA in ranitidine could increase the risk of cancer, hence its removal from market, but as GSK are saying (quite correctly) there is now an increasing body of robust evidence, in large real world observational studies, (since the litigation was initially raised) which show no increase in cancer rates over the PPIs, or famotidine.. (one of many papers below)
https://pubmed.ncbi.nlm.nih.gov/34251045/
Iām still at a loss to understand why such a sustained hit on the SP. You canāt win a case purely on theoretical risk, especially if the subsequent robust clinical studies have disproven the theoryā¦IMHO of courseā¦
Feels like everyone thinks the drop in SP is overdone , but guess we'll have to wait for the judges now to agree
Analysts finally catching on to what we have known for the past 6-12 months.
The chance to buy at under Ā£14 was the biggest giveaway since being able to buy Shell for under Ā£10.